Form D · Other
ClostraBio, Inc.
Chicago, IL · CIK 0001948176
Offering snapshot reported Sep 26, 2022 · SEC filing
- Reported sold
- $9.94M Offering amount: $11M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 12, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 26, 2022 | Initial | $9,935,759 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-459870
Source: Form D, filed Sep 26, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Flavin | Director, Executive |
| Jeffrey Hubbell | Director, Executive |
| Cathryn Nagler | Director, Executive |
| Brett Newswanger | Executive |
Issuer details
Industry: Other (See others in industry)
Address:
1375 W Fulton St Ste 650
Chicago, IL, 60607-1123
Chicago, IL, 60607-1123